Rexulti (Brexpiprazole), is an atypical antipsychotic that was jointly developed by pharmaceutical companies Otsuka and Lundbeck. In 2015, the FDA approved Rexulti for the treatment of schizophrenia and major depressive disorder (as an adjunct). Rexulti functions as a “serotonin-dopamine activity modulator” (SDAM) and is intended to be a superior successor to the antipsychotic Abilify (Aripiprazole) …
Geodon (Ziprasidone) is an atypical antipsychotic that was approved by the FDA in 2001 for the treatment of schizophrenia. It has since been approved to manage both manic and mixed states of bipolar disorder. In some cases, the drug is used as an antidepressant augmentation strategy for the treatment of refractory depression, as well as …
Latuda (Lurasidone) is a relatively new atypical antipsychotic that was approved in 2013 for the treatment of schizophrenia and depressive episodes in Type 1 Bipolar disorder. Many have made the argument that since this is a “newer” antipsychotic, it’s likely to be “better” than the crop of older medications on the market. While no single …
Viibryd (Vilazodone) is a drug that was developed by Merck for the treatment of clinical depression. It was approved in the United States as an antidepressant medication in 2011. It functions as an atypical serotonergic antidepressant. Although some consider it to be similar to SSRIs, it differs in that it is unlikely to cause significant …